Isracann Bioscience Inc. (ISCNF)

[pual]

Management is hiding ... one must ask himself 'From what'?

[pual]

Whenever a signoficant change and/or development impacting a company the management, if responsible and honest must issue a press release outlining the impact it may have OR NOT on the investment of the shareholder.

Whenever this government decision was made, our management should have explained their interpretation of that development relative to the company's plans.

Not doing it was at least irresponsible.

[zebra2142]

Reason for the dump -- Israeli Knesset rejected a bill decriminalizing recreational use. That is not what this company is about. Buying opportunity. https://www.jpost.com/breaking-news/cannabis-decriminalization-draft-bill-fails-to-get-knesset-majority-675182

[pual]

I must now conclude that this was a false business (to not be removed) managed by less than honest people.

To bad I at current pps I prefer to sit on my shares till I can use the loss for tax purpose. In any case, since Nov.29 2019, selling and buying, I managed not to be hurt and after I use the loss (taxes), et loss en negligeable.

I've been had but have no regret.I hope no di tories and excuses.

[pual]

Glad I sold 67% of my shares befor it did crash in recent months.

I did believe in this venture till management either did hide their problems or outright did not care about their shareholders. Even Morningstar has dropped giving an estimated value to this outfit.

I still have 33% of my shares but now have lost any trust I may have had in our management. At a dime or so, it's not even worth selling these anymore.

Hope no one was financially hurt by the behavior of our management (do not qualify, not to get in trouble).

[pual]

I wonder ... Why do management hide? Are they doing nothing or are they scared to outline what the situation is ???

I hate these managements keeping shareholders in the dark ... This is outright dishonesty.

[dminva]

wallsreetmyway the article you linked is from December 2019. I would expect this to have shown more uptick by now

[pual]

I did reduce my position by half (placing the proceeds in a much more serious stock).

Isracam still maybe of interest in God only knows when (for the moment I hold on my remaining 75,000 shares) but management does behave as if they had no control over their business and minimum (if any) respect for their shareholders. As a matter of fact, they do not even answer questions sent thru 'contact' of their website.

Very disappointed, I look for another opportunity to sell that to buy a better stock.

[pual]

I want to believe it is not but management certainly make it difficult to follow.

By the way (FWIW) MORNINGSTAR now says that fair value is $0,27

[RangerPete]

This baby is the scam of the decade. Show me the money. NOT.

[pual]

April 21, 2021 ( PPS @ $0,32)

Isracann CEO, Darryl Jones states, “… today we celebrate our official approval as foreign owners in this exciting sector. Now we can truly dig in to finalize matters and accelerate our efforts to fully enter the commercial marketplace. … now with the licensing in-place, a number of initiatives will be triggered almost immediately.

May 25, 2021 ( PPS @ $0,23 or 30% lower)

Mr Jones,
- What matters have been finalized within the last 5 weeks (at least, what progress has been made)?
- What progress has been made within these 5 weeks relatively to ‘fully enter the commercial market place’?
- What new initiatives have been ‘triggered within these 5 weeks’?
How come your work seems to have generated anything worth mentioning within these 5 weeks?

[WallStreetMyWay]

$ISCNF-As very quickly the right basically we right into its go enough an going to get high verifying future. A an reading this is better than nothing thinks always averages good altitude right on point's there you go thanks God for me you knows what I'm saying could happen may it be longs pressures average were going to see probally clearing up probally.

$ISCNF- is showing that is better to negotiation of the years of press. As this is starting to head in the right direction because here they are.

These players the revenues flow and smaller investors will jump on board.
Profits in the $57 Billion Medical Cannabis Boom?

https://www.otcmarkets.com/stock/ISCNF/news/story?e...

[pual]

For the Three and Nine Month Periods Ended February 29, 2020

To bad the company did not and still doesn't feel appropriate do the same for 2021

[pual]

Reading that is better than nothing. Let's hope it is objective enough to result as mentionned:

Profits in the $57 Billion Medical Cannabis Boom

A disruptive under-the-radar company has taken the lead in low-priced medical cannabis production that could put it on the road to massive profits.
The company has a number of extraordinary competitive advantages that convinced me to take a closer look at what it has to offer investors.
And now that I’ve done my due diligence, analyzed the company, spoken with management and even visited medical cannabis farms, I’ve concluded that early investors in Isracann Biosciences Inc. (ISCNF) could profit handsomely.
In fact, I believe Isracann Biosciences Inc. could produce potential growth of 740% or more, just like its South American counterpart PharmaCielo.

[WallStreetMyWay]

What comparts OTC market more understandings? Longterm holding isnt my excuse good voy.

https://www.otcmarkets.com/stock/ISCNF/disclosure

[WallStreetMyWay]

Hopefully as a guess so worth a fortune an a months from knows chicken. In longs. Very fortune exactly.

https://wallstreetrebel.com/wsr/native/10_reasons_you_could_make_windfall_profits_in_the_57_billion_medical_cannabis_boom/2019-12-13-15-00-00.html/?utm_campaign=ISCNF_SPG&utm_source=20804&utm_medium=native&utm_content=soaring

[pual]

Companies must file their 10-Qs 40 or 45 days after the end of their quarters. What explain that the company did not file on feb 15 (quarter ended Feb 29)

[Penny City Sharps]

They waited until after the 420 holiday to announce the news. Diamond hands.

[pual]

GLTY

[Lisacam]

I sold also and will keep very few shares

[pual]

Finally I only sold 10% of my shares. If it's kicking it must be alive. Let's see what's ahead and will not sell anamore ... for the moment.

[Lisacam]

Thanks for the follow up on it. Thank you for the information. We will see!

[pual]

They final;ly decided to show life and outline kind of a corporate update. Doesn't sound like success is right around the corner but at least they still seem to move toward it one of these days.

'“We continue to push ahead on multiple fronts. From product importation to new genetics programs on the one hand, today we also celebrate our official approval as foreign owners in this exciting sector. Now we can truly dig in to finalize matters and accelerate our efforts to fully enter the commercial marketplace'.

Let's hope they regularly keep us updated on the progress made.

At current price, if one is in no rush, that may turn out to be a great investment.

[pual]

Isracann Receives Foreign Owners License and Updates Israeli Cannabis Operations - 04/21/2021 9:00:00 AM

VANCOUVER, British Columbia, April 21, 2021 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor is pleased to announce it has been granted a Foreign Owners Cannabis License by the Israeli Minister of Health. This important event paves the way to conclude a number of outstanding key partnership and regulatory considerations in preparation for commercial operations.

In a press release issued on March 24, 2020, Isracann announced its entry into a joint venture (JV) agreement as part of a phased partnership of two near-term farm operations located in Ein Hahoresh, Israel. The agreement included an equitable sharing arrangement of both operating costs and revenue through participatory agreements comprising construction services, growing services, land lease agreements, IMCA licenses, and a number of sub agreements establishing and defining the various rights of all parties. Today’s announcement represents the removal of regulatory ownership barriers in order to fully execute the terms of the JV plan.

The highly sought-after foreign owners license significantly legitimizes the Company’s presence in Israel. There are only a small number of foreign owned sector participants who have obtained similar licencing, and Isracann is now favourably positioned to leverage certain advantages. Ownership licensing allows for greater access to domestic partnerships, increased participation in state-sponsored initiatives, and enhances access to financing. It also simplifies the Company’s ability to undertake domestic acquisitions, including the conclusion of its planned purchase of a third-party participant in the JV which would result in Isracann increasing its ownership position to 50%.

In related news, the Company has concluded all requisite construction and infrastructural installations in preparation for the commencement of planting and subsequent production at its Hefer Valley-based Ein Hahoresh Farm. Largely due to COVID-19 related delays, Isracann has a final regulatory hurdle to conclude which appears to be moving closer to conclusion. Based on discussions with our regional consultants, we are waiting for an inspection by law enforcement officials and concurrent Ministry of Health approvals. It is our understanding that scheduling for the inspection is imminent. Upon receipt, Isracann will have full approval to begin planting.

Regarding the recently announced medical cannabis import partnership LOI, Isracann is working diligently with the Israeli partner to conclude the agreement for the importation of Canadian products on an expedited basis. Additionally, Isracann is finalizing an agreement with its Canadian partners to secure high-grade genetic material for introduction into its Israeli-based genomics program. While regional strains have certain inherently excellent traits, Isracann aims to broaden product diversity, and through expert agronomy to achieve a selection of world-class offerings.

Isracann CEO, Darryl Jones states, “We continue to push ahead on multiple fronts. From product importation to new genetics programs on the one hand, today we also celebrate our official approval as foreign owners in this exciting sector. Now we can truly dig in to finalize matters and accelerate our efforts to fully enter the commercial marketplace. We’ve been in communication with all the relevant parties and now with the licensing in-place, a number of initiatives will be triggered almost immediately and should result in an accelerated pace towards revenue generation. We have to admit that we always thought the pandemic would create a delay, and it could have been worse. In the meantime, we have by no means been standing still and have used the opportunity to invest in added value and develop our relations throughout the region. Once again we thank our Israeli team of consultants and stakeholders who have proven to be invaluable at representing our interests so effectively and who share our vision for success.”

Further to the Company’s news release on January 11, 2021, the Company has issued 6,123,563 warrants pursuant to its incentive program. Each warrant entitles the holder thereof to acquire one additional common share of the Company at $0.50 per share for 24 months from the date of issuance.

ON BEHALF OF THE BOARD OF DIRECTORS

“Darryl Jones”

Darryl Jones
Chief Executive Officer and President

[pual]

I know the company doesn't care about their shareholders and do no even take time to answer questions sent to them. This being said I did (on my gradual way out or capitulation wanted to send them the following message on their useless Internet 'contact' site:

I do not know why I write in here again (you never follow up anyhow) but I have good news for you. If you were hoping for capitulation of your shareholders, you are successful. A friend of mine got rid of all his shares recently and I am working toward selling half my base (at least) from now on. Fortunately my avg cost was low enough (21,8 cents) and I am not YET losing. No thanks for your total disrespect of your shareholders.

I know it will give nothing but it pleases me to do it.

[Lisacam]

I think 4/20 is perfect timing to cut the cord and take my losses! I will not get back into this again. I will put my money on Cgc . ??

[pual]

I also getting concern. Either they are in trouble or they want us to sell our shares by not offering any transparency.

Last significant (???) news was 2 months ago (Isracann Completes Phase One Construction at Cannabis Facility in Israel) and notwithstanding the hiring of a communication firm we cannot even get an accuse de reception postig a question on their (contact) Internet site.

From solid believer initially I also wonders what to do with my devalued shares (even if pps is at my avg cost right now)

[Lisacam]

I am just about done with this company! ??

[pual]

Empire Communications Group is paid for what? More than 1 month with no news whatsoever (the last one only was a PR talking about non directly company related topics). Worst even, I did put a question on the Internet site (Contact) of the company and did not even get an accusé reception.

I hope we do not pay this firm very much since they do nothing.

[pual]

The Company engaged the services of Empire Communications Group
to manage Isracann’s investor relations services.

I hope they do not pay them to much. They do not even answer messages sent thru their 'CONTACT' site.

Last filing I see was made on January 28. I hope we get the next one by the end of this month.

[pual]

Is yesterday's PR coming from CNBC or CNN? Ridiculous and worrysome!

Everyone knows that the world is allowing cannabis. We did not need the company to tell us!

Not a single word referring to something meaningful relative to what the company is doing or not ???


Abstract from yesterday’s PR

Recent reports and trend data which offers great promise for the future of cannabis

United Nations (UN) drug policy-making body the (CND) voted to remove cannabis from the strict control measures

U.S. House of Representatives voted to decriminalize cannabis at the federal level. Subsequently the U.S. House approved the Medical Marijuana Research Act, that addresses unnecessary impediments to medical research.

Cannabis reform legislation is achieving increasing support in the U.S. and internationally.
BDSA forecasts global cannabis sales will grow at CAGR of more than 17%.
Israel reopened most of its economy on March 7th. Bars and restaurants, event halls, sporting events, hotels and schools could reopen with some local restrictions.

[pual]

VANCOUVER, British Columbia, March 18, 2021 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”), an Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor, is extremely pleased by recent reports and trend data which offers great promise for the future of cannabis both in Israel and major western markets.

Recent reports indicate a growing movement towards recreational cannabis legalization in Israel as part of a growing global trend and economic force. In December 2020, the United Nations (UN) drug policy-making body the Commission on Narcotic Drugs (CND) voted to remove cannabis from the strict control measures under schedule IV of the?1961 Single Convention on Narcotic Drugs.

At virtually the same time, the United States

voted to remove cannabis from Schedule IV whereby the U.S. House of Representatives voted to decriminalize cannabis at the federal level by removing it from the Controlled Substances?Act, pursuant to the Marijuana Opportunity Reinvestment and Expungement (MORE) Act. Subsequently the U.S. House approved the Medical Marijuana Research Act, bipartisan legislation that addresses unnecessary impediments to medical research. It remains to be seen if the MORE Act and other legislation will advance in the U.S. Senate in 2021. However, this ongoing activity sends a clear message that cannabis reform legislation is achieving increasing support in the U.S. and internationally.

Economically, BDS Analytics (BDSA) recent market forecast noted global cannabis sales reached nearly $21.3 billion in 2020, an increase of 48% over 2019 sales of $14.4 billion. BDSA forecasts global cannabis sales will grow from $21.3 billion in 2020 to $55.9 billion in 2026, a compound annual growth rate (CAGR) of more than 17%.

Concurrently, Israel reopened most of its economy on March 7th as part of its final phase of lifting coronavirus lockdown restrictions, some of them in place since September. Bars and restaurants, event halls, sporting events, hotels and schools that had been closed to the public for months could reopen with some local restrictions. This action is aimed at spurring economic resurgence and will serve to kickstart regional business opportunities as the country moves out of coronavirus lockdown towards post-virus normalization.

Isracann COO, Matt Chatterton, notes, “We applaud the growth and depth of these historic actions that are trending positively for our industry. As we recently noted, domestic Israeli recreational cannabis legalization could literally grow our potential consumer market by a growth factor thirty times larger than the current medicinal market. We believe the political will is there, and the return to more normalized business and social activities is bound to rapidly spur renewed cannabis industry activity and growth. We anticipate 2021 as a year that could unlock the promise of a once-in-a-lifetime opportunity for value generation across the sector. We are truly delighted to see so many indicators continuing to align in such a positive and timely manner.”

[pual]

I did ask a question to the company, both publicly (herein) and privately (company internet site) but apparently answering is not important anymore (months ago they were answering).

I own plenty of shares and remain confident in the future of the company but believe that, considering the type of info given (LOI, optimism regarding future, readiness to commence production, govenment rulings, ...), transparency should be a must for the company.

Obviously no pumping is even suggested, just FACTUAL regular updates of these evasive informations presumably being followed thru.

My understanding is that the company pays an external firm to handle shareholder's and market's questions. I would assume that receiving at least an 'accusé réception' would make this expense look justified.

[pual]

This note should be read by the company. 'PUMPING' should not be an acceptable behavior but neighter should lack of continuous appropriate transparency and keeping shareholders aware of what is going on or not.

FIRST: Mid February you issue a NR :
'The Ein Hahoresh farm operations and construction teams recently expanded the onsite post-harvest facility ... . Subject to final Security and Ministry of Health approvals ... the Company is preparing the property for imminent production activities ... Isracann and its local consultants have scheduled the commencement of planting for EARLY MARCH ... subject to the timely receipt of final government approvals.

We now are MID MARCH

SECOND: March 3, the company signed a 'non-binding LOI outlining an importation sales agreement with a major Israeli medical cannabis company. Has any progress been made since then, considering it only was a NON-BINDING LOI?

Whatever did happen (or not) relative to these 2 news releases, it should now be time to update your shareholders.

1- Has planting started as planned and if not, what is your expectation relative to the 'receipt of final government approvals'.

2- What is the plan for the LOI signed 2 weeks ago?

3- From what we see in the news, COVID is much less of an issue in Israël. Is that still a factor in executing whatever plan you have?

[pual]

I very well understand that but whenever they finally start generating revenues, it should cost a lot more to get shares. Not to be forgotten: Market cap is currently only $48,5M CDN ($39M US)

As I said, I am in as is till year end and by then, revenues should be significant (I hope and believe) easily justifying a much bigger market cap (PPS).

GLTA

[pual]

I understand. That's why current market cap is only CDN $48,5M (US $39M).

I expect revenues to be relatively significant by year end therefore seing a quite higher market cap (PPS).

Difficult legislative environment and COVID have slowed the take off of production, revenues and exports but I believe the next months will these behind us within the next few months.

This being said, I have no crystal ball ???

[RangerPete]

That’s pretty high for a company with no revenues.

[pual]

Personally I am extremely confident relative to this stock.

Recently IPOT (I'm in Canada) went from making 21 to 32% of my portfolio . cost un$034 cdn) and I will wait for the finacials of the current FY (1Q 22) before I decide how LONG or not I will be with this investment.

I am extremely confident because from what I can see, the company does all the right moves in an extremely difficult environment (Israël laws and rules, COVID_19, ...) but they will come thru and be able to exploit a very large market in Europe in particular.

I st and wait, hoping that along the way, the company will keep being transparent, informing their shareholders.

Finally, a market cap of less than CDN $ 50M leaves a lot of space for growth.

GLTA

[Penny City Sharps]

Isracann has to be THEE most overlooked cannabis company. An Israel seed to sale company, what more needs to be said? I wouldn't want to be without shares whenever the fireworks start, especially with stimulus money entering the markets soon.

[pual]

Need for a general corporate update

I own plenty of this stock, have no intent to sell and am confident that some time in the future this will be a highly profitable stock to own. This being said, the company should clarify (GENERAL CORPORATE UPDATE) what their plan of action is, WHAT OBSTACLES THEY FACE (including legislative concerns) and how they intend to progress from here on, outlining a probable time table.

Arriving to the end of the quarter, such a corporate update including the plan date for the next financial results filing would be appropriate.

Again, that seems to be a great stock to own but it seems the company cannot progress fast enough for God and the management only knows why. TRANPARENCY PLEASE!

Here after is bits and pieces of news in 2021 sounding like excuses not to progressing fast enough.

Isracann Announces Launch of Early Warrant Exercise Incentive Program 01/19/2021
announces it has implemented a warrant exercise incentive program designed to encourage exercise of up to 20,574,216 of its outstanding share purchase warrants expiring on September 30, 2021 (the “Warrants”). The Company will amend the exercise price of the Warrants from $1.02 per common share of the Company (each, a “Share”) to $0.30 per Share, subject to acceleration

Isracann Well Positioned for Israel’s Cannabis Sector Growth in 2021 01/19/2021
the Company and its regional partners are moving rapidly towards industrial-scale operations capable of servicing both the domestic and increasingly important European export markets in 2021.

Isracann Prepares to Import Canadian Cannabis into Israel and Europe 02/16/2021
the Company has determined to advance foreign importation of Cannabis into Israel in response to perceived opportunity.

Isracann Completes Phase One Construction at Cannabis Facility in Israel 02/25/2021
Hefer Valley-based Ein Hahoresh Farm is in full readiness to commence growing and production activities.. Subject to final Security and Ministry of Health approvals

Isracann Prepares for Recreational Cannabis Opportunity in Israel 02/25/2021
report on the prevalence of media reports and public optimism regarding the future of recreational Cannabis building momentum across Israel.

Isracann Signs Cannabis Importation LOI with Major Israeli Manufacturer 03/03/2021
announce it has entered a non-binding Letter of Intent outlining an importation sales agreement with a major Israeli medical cannabis company

[pual]

Added 50% to my base. May take some months but I'm extremely confident that this stock is way under priced right now. I foresee a doubling +++ of the current pps before the end of the year

[pual]

Kind of nice … There a storm out there, all boards are dark read and IPOT doesn't move. That says a lot!

[pual]

I like the attitude of our management. They do not sit on their a.. waiting for things to develop, they do whatever is needed to progress, waiting for expected developments to occur.

I believe the PPS could double + before year end.

Here what I like the most in today's NR :

'The importance of imported sales through Isracann include:
- immediate revenue generation,
- introduction of new brands to the Israeli market, and
- the ability to trial Isracann’s processing facilities and domestic distribution arrangements.'

'The need to identify new logistics, systems and business opportunities prior to the anticipated explosive growth potential posed by recent recreational legalization efforts and pending access to major European markets are considered critical strategic factors for the sustainable growth of the Company.'

[pual]

Isracann Signs Cannabis Importation LOI with Major Israeli Manufacturer - 03/03/2021 9:00:00 AM

VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor is pleased to announce it has entered a non-binding Letter of Intent (LOI) outlining an importation sales agreement with a major Israeli medical cannabis company.

The proposed relationship is with one of the leading cannabis product manufacturers in Israel, who for commercial reasons can not be identified at this time. Imported goods will consist of premium Canadian cannabis via Isracann’s agreement with Costa Canna Group’s cultivation subsidiary, United Greeneries Ltd. The arrangement includes the provision that all imported material will be sold under the Isracann brand with subsequent products locally manufactured by the proposed partner in accordance with Israeli GMP requirements.

Isracann’s Canadian import/export agreement provides exclusive access to established specialty strains including ultra high THC, high CBD, balanced, and specialty craft-grown strains which will eventually serve as alternative product offerings concurrent to the introduction of its own premium Israeli grown and branded products upon the commencement of cultivation from local Isracann-owned farm facilities.

The importance of imported sales through Isracann include immediate revenue generation, introduction of new brands to the Israeli market, and the ability to trial Isracann’s processing facilities and domestic distribution arrangements. The need to identify new logistics, systems and business opportunities prior to the anticipated explosive growth potential posed by recent recreational legalization efforts and pending access to major European markets are considered critical strategic factors for the sustainable growth of the Company.

The Israeli market for medical cannabis continues to grow at a rapid pace. Now with over 80,000 medical patients (IMCA data), the domestic growers are struggling to keep up with demand. Recent news regarding recreational legalization efforts position the local industry to grow to an indicated 2.5 million potential consumers.

Company CEO Darryl Jones states, “The agreement in-place is straightforward and is a win-win for both parties. The inexorable growth in demand for medical cannabis products combined with the potential recreational and export market scenarios means that the serious operators are making decisions right now as to how they will manage demand stressors in future. We have been speaking with several of the larger players in the sector and todays announcement is likely to be joined with some additionally positive commercial decisions in the coming months. All of which means that we appear to be in the right place at the right time. Our team in Israel are well-connected and ensuring we are aware of the numerous opportunities and prevailing trends that allow us to act proactively. Strategically, we remain focused on securing agreements and opportunities in order to firmly position Isracann where we can best grow our value proposition and capitalize on the unfolding events in this exciting region.”

[Pennyes]

IsraCann, can!
well positioned for the big upside run!...Nice cup and handle pointing the upside!..

immediate target 0.39 and 0.55 short term target $1-2!

[pual]

Isracann Prepares for Recreational Cannabis Opportunity in Israel
02/25/2021 9:00:00 AM

VANCOUVER, British Columbia, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor is pleased to report on the prevalence of media reports and public optimism regarding the future of recreational Cannabis building momentum across Israel.

As the world turned the page on 2020, reports of recommendations from an interministerial team led by Justice Minister Avi Nissenkorn offered recommendations for the legalization of cannabis for recreational use within nine months while balancing “liberalism and responsibility.” “It’s time to make progress and legalize cannabis in Israel,” Nissenkorn said. “This is a significant, holistic and responsible reform, which shows the State of Israel isn’t ignoring reality and is going in the footsteps of developed countries.” Deputy Attorney General Amir Merari said the government’s opinion is to favor legalization over decriminalization, which is more common in other countries, since “decriminalization doesn’t provide a solution for problems such as the black market.”

In a country that continually punches above its weight, Israel already boasts some compelling world records such as the highest amount of Venture Capital per capita (IVC-Online), highest number of start-ups per capita (IVC-Online), highest percentage of GDP in R&D investments (4.2%) (Economic Times), #3 in NASDAQ listed companies (after USA & China) (Deloitte), 2nd most innovative nation (World Economic Forum), and the highest number of patents per capita( Bloomberg), so its little wonder that as far back as 2017 surveys showed it also held the record for the world’s highest ratio of marijuana users with 27% of the population aged 18-65 identifying as recreational users (US News, Times of Israel).

With a population of approximately 9 million persons, legalization would immediately and dramatically increase the domestic retail market to almost 2.5 million potential customers. Current domestic shortages for the estimated 80,000 medical users have already created pent-up demand and an extraordinary prospect for Isracann. With excellent ties to Canada, the Company has positioned itself through agreements in-place to import bulk materials, and upon legalization to deliver finished products into Israel just as demand is poised to explode. This provides Isracann the opportunity to offer a near term capacity to service the anticipated growth in consumer demand while ramping domestic production as its Hefer Valley operation as the year progresses.
Currently, Isracann has completed construction of its 55,0000 sq. ft. phase one farm facility and is in the process of finalizing police and health ministry permits prior to the commencement of planting. Isracann is committed to servicing the needs of the Israeli medical market and the production output of the phase one facility remains dedicated to this commitment. To service the recreational market, Isracann’s 110,000 sq. ft. phase two facility construction is well underway with the ability to rapidly complete the build-out and commence operations solely subject to demand, Phase two requires minimal capital outlay to complete, and the post harvest facility at the Ein Hahoresh farm has already been completed with a capacity to process the combined total output from the overall 165,000 sq. ft. farm operation. In addition, landholding options offer 2,000,000 sq. ft. of adjoining property which provides scalability to meet virtually any increase in future market demand.

“We’re juggling a growing number of exciting activities alongside a wealth of strategic opportunities increasingly in play, and the year is barely halfway through the first quarter,” notes Isracann COO, Matt Chatterton. “With an ability to import everything from premium cannabis genetics to bulk biomass and eventually as liberalization continues, even finished goods, we are ready to begin processing inbound logistics almost immediately. Once the supply chain is flowing, we have sales agreements that will kick into gear and we commence revenue generation. We have a straightforward police inspection of the farm to complete and then seedlings go in the ground. We are on-track for predicable timelines to harvest and a dramatic increase in overall supply which should quickly meet our domestic needs and allow us to turn towards the high value export markets of Europe. We have lots of choices to leverage our value chain and in many ways, we are blessed with an abundance of opportunity.”

[pual]

Notwithstanding its very slow start but keeping an eye in its small market cap, Isracann's PPS should more or less triple within current year.

A $ 150M market cap by the end of 2021 is far from being unlykely.

Patience will be rewarded

[goupupup]

https://isracann.com/2021/02/16/isracann-completes-phase-one-construction-at-cannabis-facility-in-israel/

[goupupup]

P ..Just in case you missed any of these articles ..

VANCOUVER, British Columbia, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer is pleased to provide a year end summary of activities and outlook for 2021.

There is a sense of relief that 2020 is now behind us. Over the course of the past year, the impact of COVID-19 has been felt around the globe and will undoubtedly continue to impact countless lives and entire economies for years to come. While many difficulties remain before us all, a guarded optimism is growing daily. The challenges that directly impacted our venture were principally logistical and operational in nature and affected most of the sector equally. Given the Israeli governments increasingly pragmatic outlook regarding cannabis we remain extremely optimistic regarding our ability to achieve our strategic goals for the new year.

In consideration of the disruptive nature of the pandemic, Isracann is nonetheless extremely pleased to have made continued progress at both its domestic operations. At our early-stage Nir, Israel farm, the Company was required to realign elements of its submission to the Settlement Commissioner for the Nir region, which was expedited via the invaluable aid of our regional consultants. This process has paved the way for a formal application to the Ministry of Health. In all other respects the project is poised for fast-tracked completion with commencement of operations to occur as soon as approval is received.

The agreement and commitment to accelerate the completion of the flagship Hefer Valley-based Ein Hahoresh Farm has proven to be a key driver for the Company. With 165,000 sq. ft. of greenhouse canopy and extensive processing capability in-place, the Company and its regional partners are moving rapidly towards industrial-scale operations capable of servicing both the domestic and increasingly important European export markets in 2021.

Per recently amended regulations that require all physical facilities to be completed and approved prior to planting, the construction activities at the Ein Hahoresh farm expanded the onsite post-harvest facility in preparation for commencement of operations and increased demand from growing domestic and export markets. We are well poised to, in the short term, complete the facility and receive the required Security and Ministry of Health approvals to acquire our farm operating license and start planting. Consequently, Isracann and its local consultants are currently scheduling the commencement of planting in March to coincide with the start of optimal climatic conditions. Additionally, applications for certification of Isracann as foreign cannabis cultivation license owners were submitted to the Ministries of Security and Health, which upon acceptance, will result in Isracann’s ability to formally complete any remaining aspects of our joint venture acquisition.

While completion of our farms is the primary focus of the company, we have been actively initiating and expanding our visibility and relationships across the region and onwards into Europe. Our goal has been to establish infrastructural agreements aimed at launching Isracann onto the world stage as a truly international cannabis enterprise. As these pending activities are commercial in nature, and include multiple parties, we look forward to announcing further details outlining our expanded strategic outlook for the coming year as soon as possible.

Concurrently, the domestic legislative, regulatory, and societal environment regarding cannabis production, processing, distribution, and sales within Israel continues to improve as do the opportunities for export operations. Last year saw several landmark rulings and accelerated momentum that is rapidly transforming this emerging sector into a respected national industry.

It is also worth mentioning that Israel has been noted as an early leader in the distribution of coronavirus vaccinations, and this appears to be driving optimism for the entire business community throughout the region. Isracann and its team of professional consultants are confident this will aid initial sales projections upon entry into a domestic marketplace which is markedly more robust than ever before.

Company CEO Darryl Jones comments, “Since our decision to enter the market sector in Israel just 20 short months ago, we have seen cannabis reform, including major advances in legalization, production and distribution. We’ve also seen the door opening up for export sales, and a wholesale shift in cultural acceptance. And yet we have had to deal with some setbacks as the regional governments come to terms with new regulations and the impact of a global pandemic. But one thing to remember is that this is just the playing field, and it is the same field for everyone in the sector. As players, we have engaged top industry professionals to consult on our behalf, incorporated leading agronomic experts to show us the true path to product excellence, and ensured our leadership includes a strong mix of business and production expertise. We have a team with big league knowhow and home field advantage, and this all translates into ability and confidence. We are well positioned and well financed and are committed to ensuring that 2021 is the year Isracann gets fully into the game and starts to deliver the returns we know its capable of. With that vision firmly in-place, we thank all our supporters for your continued trust as we forge ahead to make this year an outstanding opportunity for value creation through the intelligent application of capital into predictably growth-focused areas of the global cannabis industry.”

ON BEHALF OF THE BOARD OF DIRECTORS “Darryl Jones”
Chief Executive Officer and President

About Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF)
Isracann is an Israeli-based cannabis company focused on becoming a premier cannabis producer offering low-cost production targeting undersupplied, major European marketplaces. Based in Israel's agricultural sector, Isracann will leverage its development within the most experienced country in the world with respect to cannabis research. The Company has secured agreements within Israel for medicinal marijuana cultivation. For more information visit: www.isracann.com.

https://isracann.com/2021/01/11/isracann-announces-launch-of-early-warrant-exercise-incentive-program-and-repricing/

https://isracann.com/2021/02/02/isracann-prepares-to-import-canadian-cannabis-into-israel-and-europe/

[pual]

My the way, I am an INVESTOR in companies I consider promissing (Cannabis, health and environment).

This being said, I always keep ONE (1)toy or long shot pink stock seemingly promising even if it involves a startup or quasi startup. I generally bet about $5,000 on such a 'toy' filling my time doing more serious work on my pc.

A couple of months ago I found one (GRST - Ethema Health Corp -
OTC Pink,US) that is turning out to be quite interesting.

Up to now I have double my bet and I now consider it to be a risky but serious INVESTMENT IN THE MAKING.

Just tought sharing this with you ...